Your browser doesn't support javascript.
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
Rogiers, Aljosja; Pires da Silva, Ines; Tentori, Chiara; Tondini, Carlo Alberto; Grimes, Joseph M; Trager, Megan H; Nahm, Sharon; Zubiri, Leyre; Manos, Michael; Bowling, Peter; Elkrief, Arielle; Papneja, Neha; Vitale, Maria Grazia; Rose, April A N; Borgers, Jessica S W; Roy, Severine; Mangana, Joanna; Pimentel Muniz, Thiago; Cooksley, Tim; Lupu, Jeremy; Vaisman, Alon; Saibil, Samuel D; Butler, Marcus O; Menzies, Alexander M; Carlino, Matteo S; Erdmann, Michael; Berking, Carola; Zimmer, Lisa; Schadendorf, Dirk; Pala, Laura; Queirolo, Paola; Posch, Christian; Hauschild, Axel; Dummer, Reinhard; Haanen, John; Blank, Christian U; Robert, Caroline; Sullivan, Ryan J; Ascierto, Paolo Antonio; Miller, Wilson H; Stephen Hodi, F; Suijkerbuijk, Karijn P M; Reynolds, Kerry L; Rahma, Osama E; Lorigan, Paul C; Carvajal, Richard D; Lo, Serigne; Mandala, Mario; Long, Georgina V.
  • Rogiers A; Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia.
  • Pires da Silva I; Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia.
  • Tentori C; Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia.
  • Tondini CA; FROM Fondazione per la Ricerca Ospedale Maggiore, Bergamo, Italy.
  • Grimes JM; Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Trager MH; Columbia University Irving Medical Center, New York City, New York, USA.
  • Nahm S; Columbia University Irving Medical Center, New York City, New York, USA.
  • Zubiri L; The Christie NHS Foundation Trust, Manchester, UK.
  • Manos M; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
  • Bowling P; Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • Elkrief A; Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • Papneja N; Segal Cancer Centre Jewish General Hospital, McGill University, Montreal, Québec, Canada.
  • Vitale MG; Segal Cancer Centre Jewish General Hospital, McGill University, Montreal, Québec, Canada.
  • Rose AAN; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
  • Borgers JSW; Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada.
  • Roy S; Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Mangana J; Gustave Roussy and Paris-Saclay University, Villejuif, France.
  • Pimentel Muniz T; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • Cooksley T; Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada.
  • Lupu J; The Christie NHS Foundation Trust, Manchester, UK.
  • Vaisman A; Gustave Roussy and Paris-Saclay University, Villejuif, France.
  • Saibil SD; Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada.
  • Butler MO; Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada.
  • Menzies AM; Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada.
  • Carlino MS; Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia.
  • Erdmann M; Royal North Shore Hospital and Mater Hospital, Sydney, New South Wales, Australia.
  • Berking C; Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia.
  • Zimmer L; Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia.
  • Schadendorf D; Comprehensive Cancer Center Erlangen - EMN, University Medical Center Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
  • Pala L; Comprehensive Cancer Center Erlangen - EMN, University Medical Center Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
  • Queirolo P; University Hospital Essen & German Cancer Consortium, Partner Site, Essen, Germany.
  • Posch C; University Hospital Essen & German Cancer Consortium, Partner Site, Essen, Germany.
  • Hauschild A; European Institute of Oncology, Milan, Italy.
  • Dummer R; Division of Melanoma, Sarcomas and Rare Tumors, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
  • Haanen J; Technical University of Munich, German Cancer Consortium (DKTK), Munich, Germany.
  • Blank CU; University Hospital Schleswig-Holstein, Kiel, Germany.
  • Robert C; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • Sullivan RJ; Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Ascierto PA; Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Miller WH; Gustave Roussy and Paris-Saclay University, Villejuif, France.
  • Stephen Hodi F; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
  • Suijkerbuijk KPM; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
  • Reynolds KL; Segal Cancer Centre Jewish General Hospital, McGill University, Montreal, Québec, Canada.
  • Rahma OE; Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • Lorigan PC; University Medical Center Utrecht, Utrecht, The Netherlands.
  • Carvajal RD; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
  • Lo S; Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • Mandala M; The Christie NHS Foundation Trust, Manchester, UK.
  • Long GV; University of Manchester, Manchester, UK.
J Immunother Cancer ; 9(1)2021 01.
Article in English | MEDLINE | ID: covidwho-1038424
ABSTRACT

BACKGROUND:

Patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The impact of immune checkpoint inhibition (ICI) on the severity of COVID-19 illness is unknown. The aim of this study was to investigate whether ICI confers an additional risk for severe COVID-19 in patients with cancer.

METHODS:

We analyzed data from 110 patients with laboratory-confirmed SARS-CoV-2 while on treatment with ICI without chemotherapy in 19 hospitals in North America, Europe and Australia. The primary objective was to describe the clinical course and to identify factors associated with hospital and intensive care (ICU) admission and mortality.

FINDINGS:

Thirty-five (32%) patients were admitted to hospital and 18 (16%) died. All patients who died had advanced cancer, and only four were admitted to ICU. COVID-19 was the primary cause of death in 8 (7%) patients. Factors independently associated with an increased risk for hospital admission were ECOG ≥2 (OR 39.25, 95% CI 4.17 to 369.2, p=0.0013), treatment with combination ICI (OR 5.68, 95% CI 1.58 to 20.36, p=0.0273) and presence of COVID-19 symptoms (OR 5.30, 95% CI 1.57 to 17.89, p=0.0073). Seventy-six (73%) patients interrupted ICI due to SARS-CoV-2 infection, 43 (57%) of whom had resumed at data cut-off.

INTERPRETATION:

COVID-19-related mortality in the ICI-treated population does not appear to be higher than previously published mortality rates for patients with cancer. Inpatient mortality of patients with cancer treated with ICI was high in comparison with previously reported rates for hospitalized patients with cancer and was due to COVID-19 in almost half of the cases. We identified factors associated with adverse outcomes in ICI-treated patients with COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immune Checkpoint Inhibitors / COVID-19 / Neoplasms Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Year: 2021 Document Type: Article Affiliation country: Jitc-2020-001931

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immune Checkpoint Inhibitors / COVID-19 / Neoplasms Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Year: 2021 Document Type: Article Affiliation country: Jitc-2020-001931